Article: Israeli firm to market generic version of Pfizer antifungal drug.

Byline: Anthony Cronin

Jan. 18--An Israeli pharmaceutical company said Monday that it has been awarded approval to market a generic version of Pfizer Inc.'s antifungal drug Diflucan.

Teva Pharmaceutical Industries Ltd. said the federal Food and Drug Administration granted final approval for the company's Fluconazole Injection available in 2-milligram-per-milliliter 200- and 400-milligram bags. The pharmaceutical maker said that a final launch date has not been determined. Shares of Teva, which trade on the NASDAQ electronic exchange, closed the day's trading at $28.53 a share, up 8 cents from the prior day's trading.

Teva, based in Jerusalem, ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!